EMPLICURE AB (PUBL)

Inactive Instrument

Highlights Emplicure AB (publ)

Equities

EMPLI

SE0015812391

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Emplicure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Emplicure Set to Delist in Sweden as Goldcup 33922 Starts Squeeze Out	Nov. 09	MT
Emplicure Investor Consortium to Transfer Stake to Holding Company	23-10-23	MT
Emplicure AB Receives Research Grant of SEK 1.0 Million from Vinnova	23-09-15	CI
Emplicure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Emplicure AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Emplicure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-23	CI
Emplicure and OnDosis Form Partnership to Develop Better Pain Treatments	23-01-20	CI
Emplicure AB Announces Results from the Exploratory Clinical PK Study of Its Drug Candidate Empli03	22-12-22	CI
Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure's First Clinical Pharmacokinetic Study for EMPLI03	22-11-29	CI
Emplicure Engages Erik Penser Bank as Liquidity Provider	22-11-23	CI
Emplicure AB Reports Dosing in the First Phase I Pharmacokinetic Study for EMPLI03, Intended for the Treatment of Moderate to Severe Pain	22-10-27	CI
Uk Authorities Approves Emplicure's Application to Conduct Clinical Pharmacokinetic Study of Empli03	22-09-06	CI
Emplicure AB Signs Development Agreement with Uppsala University Regarding Biological Medicines	22-04-05	CI
Emplicure AB Announces A Patent Is Set to Be Granted in Australia for Inhalation of Pharmaceuticals	22-04-01	CI
Emplicure AB Announces Ready for Gmp Manufacturing for the Clinical Study	21-12-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW